Adverse events profiles of liposomal and conventional doxorubicins: An updated comprehensive analysis of the FDA adverse event reporting system

Author:

Li Zhengjun1,Su Huiling2,Jia Jing3,Mao Yuxiang4,Zhu Riran3

Affiliation:

1. Department of Dermotology, Qilu Hospital, Shandong University, Jinan, Shandong, China

2. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

3. Department of Pharmacy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China

4. Medical school, Kunming University of Science and Technology, Kunming, Yunnan, China

Abstract

Abstract The clinical application of doxorubicin (DOX) is constrained by its side effects. Liposomal doxorubicin was developed to mitigate these limitations, showing improved toxicity profiles. However, the adverse events associated with liposomal doxorubicin and CDOX have not yet been comprehensively evaluated in clinical settings. The FAERS data from January 2004 to December 2022 were collected to analyze the adverse events of liposomal DOX and CDOX. Disproportionate analysis and Bayesian analysis were employed to quantify this association. Our analysis incorporated 68,803 adverse event reports related to liposomal doxorubicin and CDOX. The relative odds ratios (RORs, 95%CI) for febrile neutropenia associated with CDOX, Doxil®/Caelyx®, and Myocet® were 42.45(41.44;43.48), 17.53(16.02;19.20), and 34.68(26.63;45.15) respectively. For cardiotoxicity, they were 38.87(36.41;41.49), 17.96(14.10;22.86), and 37.36(19.34;72.17). For Palmar-Plantar Erythrodysesthesia (PPE), the RORs were 6.16(5.69;6.68), 36.13(32.60;40.06), and 19.69(11.59;33.44). Regarding onset time, significant differences adverse events including neutropenia, PPE, pneumonia and malignant neoplasm progression. This study indicates that the use of CDOX warrants careful monitoring for cardiotoxicity, PPE, and interstitial lung disease, especially with Doxil®. Additionally, the onset time of febrile neutropenia, malignant neoplasm progression, and pneumonia associated with liposomal doxorubicin merits particular attention. Continuous surveillance, risk evaluations, and additional comparative studies between liposomal doxorubicin and CDOX are recommended.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3